Novo Nordisk Raises Guidance Amid Surging Demand for Diabetes, Obesity Drugs

[ad_1]

Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its Ozempic diabetes drug and Wegovy obesity treatment continued to rise.

[ad_2]

Source link